Serum Institute Of India To Acquire 20% Stake In IntegriMedical
IntegriMedical has developed a US patented needle-free
Injection System (N-FIS) that utilises a high-velocity jet stream using
mechanical power to effectively and consistently administer biologics and
drugs, Serum Institute of India (SII) said in a statement.
Vaccines manufacturer Serum Institute of India (SII) on
Friday said it is acquiring 20 per cent stake in IntegriMedical, to advance
needle-free injection system technology.
SII To Acquire 20% in IntegriMedical
IntegriMedical has developed a US patented needle-free
Injection System (N-FIS) that utilises high-velocity jet stream using
mechanical power to effectively and consistently administer biologics and
drugs, Serum Institute of India (SII) said in a statement.
The company, however, did not disclose the financial details
of the transaction.
Comments
Post a Comment